Clinical Trials Arena on MSN
AbbVie’s skin disease drug posts Phase III win as market competition heats up
This late-stage readout comes as companies explore the potential of novel mechanisms of action in HS.
1don MSN
AbbVie’s skin disease drug hits phase 3 goal, but efficacy falls short of benchmarks: analyst
AbbVie Inc. ABBV on Thursday shared topline results from its Phase 3 INTREPID study evaluating lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). The ...
"It just got so big, the size of an iPhone 16 Pro Max".
From joint pain to skin changes, your body can experience the condition in ways you might not expect.
For people living with hidradenitis suppurativa (HS), a chronic inflammatory skin condition that can cause painful lumps, ...
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Our understanding of this complex immune-mediated disease continues to deepen; while it involves intricate pathogenic ...
A 2026 review of 25 studies involving 373,689 people with hidradenitis suppurativa found higher cardiovascular risks. Learn ...
A large real-world analysis of electronic health records using the TriNetX network indicates that patients with hidradenitis ...
A tooth abscess is a serious bacterial infection that requires dental treatment with antibiotics and may need draining or tooth removal. Without treatment, it can spread to other parts of your face ...
The "mawashi" (loincloth) used in festivals is in a state where bacteria can easily multiply due to long hours of intense ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results